Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 370 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: OVARY Clear all
Completed Phase 2 Interventional Results available

Triptorelin for Ovary Protection in Childhood Onset Lupus

NCT00124514
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Triptorelin Pamoate, placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting Not applicable Interventional

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

NCT06049420
View directory record Official record
Conditions
Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
Interventions
Lifestyle counseling and coaching
Behavioral
Lead sponsor
West Virginia School of Osteopathic Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lewisburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial

NCT03380091
View directory record Official record
Conditions
PCOS, Depression, Vitamin D Deficiency, Insulin Resistance
Interventions
Metformin, Vitamin D
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 30, 2026, 12:03 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

NCT05001282
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
ELU001
Drug
Lead sponsor
Elucida Oncology
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 30, 2026, 12:03 PM EDT
Terminated Phase 3 Interventional

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

NCT00350948
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Telcyta, Liposomal Doxorubicin
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Casa Grande, Arizona • Little Rock, Arkansas • Antioch, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Time Restricted Eating for the Treatment of PCOS

NCT05629858
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obesity, Overweight
Interventions
6-h Time restricted eating (TRE), Calorie restriction (CR), Control
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Ovarian Tissue Allo-transplantation

NCT06673004
View directory record Official record
Conditions
Ovarian Failure, Ovarian Insufficiency, Menopause Ovarian Failure, Menopause, Premature, Infertility, Female, Endocrine Female Infertility
Interventions
Ovarian tissue allo-transplantation
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome

NCT06050265
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Dysglycemia, Insulin Resistance
Interventions
DEXCOM Continuous Glucose Monitor (CGM)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting Not applicable Interventional

Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot

NCT07227363
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome)
Interventions
Ketogenic diet, Exogenous Ketone Supplement
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational

Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study

NCT00946140
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DCE-MRI scans
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting Phase 2 Interventional

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

NCT06268665
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Invasive Breast Cancer, Ovarian Cancer, Ovarian Cancer Stage 1, Ovarian Cancer Stage II, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Ovarian Cancer Stage IA, Ovarian Cancer Stage IB, Ovarian Cancer Stage IC, Ovarian Cancer Stage 2, Ovarian Cancer Stage 3, Ovarian Cancer Stage IIIb, Ovarian Cancer Stage IIIC, Breast Cancer Stage IIIA, Breast Cancer Invasive, Breast Cancer, Stage IA, Breast Cancer, Stage IB, Breast Cancer Stage IIA, Breast Cancer Stage IIB, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Cancer, Breast, Tumors, Breast, Mammary Cancer, Mammary Carcinoma, Breast Carcinoma, Breast Neoplasm, Malignant Breast Neoplasm, Malignant Tumor of Breast, Cancer of Ovary, Ovary Cancer, Ovary Neoplasm
Interventions
Tart Cherry Juice
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational

Blood Collection From People With Ovarian Cancer

NCT02063464
View directory record Official record
Conditions
Ovarian Cancer, Cancer of the Ovary, Ovarian Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 12:03 PM EDT
Not listed Not applicable Interventional

Polycystic Ovary Syndrome Genetics and Treatment Response

NCT01389778
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin ER, Metformin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting Phase 2 Interventional

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609
View directory record Official record
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923
View directory record Official record
Conditions
Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Interventions
Senaparib, Temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 2 Interventional

Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum

NCT00012090
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
bicalutamide, goserelin acetate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

NCT00913835
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Olaratumab, liposomal doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Joliet, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 30, 2026, 12:03 PM EDT
Not listed Phase 1Phase 2 Interventional

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

NCT00057395
View directory record Official record
Conditions
Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Neoplasms
Interventions
Aroplatin (Liposomal NDDP, L-NDDP)
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 12:03 PM EDT
Terminated No phase listed Observational

Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome

NCT01475565
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance, Insulin Sensitivity, Obesity, Pregnancy
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 30, 2026, 12:03 PM EDT
Completed No phase listed Observational

Prospective Study Assessing Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Removal of the Cervix Versus Removal of the Uterus,Ovaries and Fallopian Tubes For Treatment Of Early Stage Cervical Cancer

NCT00579787
View directory record Official record
Conditions
Cervical Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Oct 30, 2026, 12:03 PM EDT
Completed Not applicable Interventional

Heat Therapy and Cardiometabolic Health in Obese Women

NCT03644524
View directory record Official record
Conditions
Obesity, Polycystic Ovary Syndrome, Prehypertension, PreDiabetes, Cardiovascular Risk Factor, Metabolic Syndrome
Interventions
Heat therapy
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

NCT05950282
View directory record Official record
Conditions
Insulin Resistance, Polycystic Ovary Syndrome, Hyperinsulinism, Obesity, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Ali Chappell
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 12:03 PM EDT
Recruiting Phase 2 Interventional

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

NCT06677190
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
Interventions
Belzutifan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 30, 2026, 12:03 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ovarian Morphology in Girls

NCT04424576
View directory record Official record
Conditions
Amenorrhea, Oligomenorrhea, Puberty
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
9 Years to 17 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Kansas City, Missouri • Ithaca, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 30, 2026, 12:03 PM EDT